{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T20:45:45Z","timestamp":1764103545486,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:00:00Z","timestamp":1732320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s12072-024-10745-8","type":"journal-article","created":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T17:11:09Z","timestamp":1732381869000},"page":"131-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The dynamic patterns of metabolic-associated fatty liver disease and its severity and risk of cardiovascular disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Haozhe","family":"Cui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,23]]},"reference":[{"issue":"1","key":"10745_CR1","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"9","key":"10745_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","volume":"7","author":"K Riazi","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851\u2013861","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10745_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","volume":"14","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zheng Q, Zou B, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14(2):259\u2013269","journal-title":"Hepatol Int"},{"issue":"4","key":"10745_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904","journal-title":"J Hepatol"},{"issue":"5","key":"10745_CR5","doi-asserted-by":"publisher","first-page":"e042843","DOI":"10.1136\/bmjopen-2020-042843","volume":"11","author":"X Zhang","year":"2021","unstructured":"Zhang X, Wu M, Liu Z, et al. Increasing prevalence of NAFLD\/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study. BMJ Open. 2021;11(5):e042843","journal-title":"BMJ Open"},{"issue":"8","key":"10745_CR6","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","volume":"5","author":"Q Ye","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(8):739\u2013752","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10745_CR7","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCRESAHA.117.308903","volume":"121","author":"P Joseph","year":"2017","unstructured":"Joseph P, Leong D, McKee M, et al. Reducing the global burden of cardiovascular disease, part 1: the epidemiology and risk factors. Circ Res. 2017;121(6):677\u2013694","journal-title":"Circ Res"},{"issue":"25","key":"10745_CR8","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors 1990\u20132019: update from the GBD 2019 study. J Am College Cardiol. 2020;76(25):2982\u20133021","journal-title":"J Am College Cardiol"},{"issue":"4","key":"10745_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nrcardio.2017.154","volume":"15","author":"C Andersson","year":"2018","unstructured":"Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230\u2013240","journal-title":"Nat Rev Cardiol"},{"issue":"24","key":"10745_CR10","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1016\/j.jacc.2019.04.036","volume":"73","author":"Du Xin","year":"2019","unstructured":"Xin Du, Patel A, Anderson CS, et al. Epidemiology of cardiovascular disease in China and opportunities for\u00a0improvement: JACC\u00a0international. J Am College Cardiol. 2019;73(24):3135\u20133147","journal-title":"J Am College Cardiol"},{"issue":"14","key":"10745_CR11","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa2206916","volume":"389","author":"Global Cardiovascular Risk Consortium","year":"2023","unstructured":"Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273\u20131285","journal-title":"N Engl J Med"},{"issue":"10","key":"10745_CR12","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","volume":"19","author":"H Lee","year":"2021","unstructured":"Lee H, Lee YH, Kim SU, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol. 2021;19(10):2138-2147.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10745_CR13","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","volume":"17","author":"XD Zhou","year":"2023","unstructured":"Zhou XD, Targher G, Byrne CD, et al. An international multidisciplinary consensus statement on MAFLD and the risk of CVD. Hepatol Int. 2023;17(4):773\u2013791","journal-title":"Hepatol Int"},{"issue":"2","key":"10745_CR14","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1007\/s12072-021-10157-y","volume":"15","author":"GTS Guerreiro","year":"2021","unstructured":"Guerreiro GTS, Longo L, Fonseca MA, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD? Hepatol Int. 2021;15(2):380\u2013391","journal-title":"Hepatol Int"},{"issue":"11","key":"10745_CR15","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.cgh.2021.09.021","volume":"20","author":"JZK Toh","year":"2022","unstructured":"Toh JZK, Pan XH, Tay PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2022;20(11):2462-2473.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"44","key":"10745_CR16","doi-asserted-by":"publisher","first-page":"e35804","DOI":"10.1097\/MD.0000000000035804","volume":"102","author":"YH Oh","year":"2023","unstructured":"Oh YH, Jeong S, Park SJ, et al. Reversal of nonalcoholic fatty liver disease reduces the risk of cardiovascular disease among Korean. Medicine (Baltimore). 2023;102(44):e35804","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10745_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12933-022-01725-z","volume":"21","author":"J Park","year":"2022","unstructured":"Park J, Kim G, Kim H, et al. The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study. Cardiovasc Diabetol. 2022;21(1):287","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10745_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12933-022-01456-1","volume":"21","author":"H Cui","year":"2022","unstructured":"Cui H, Liu Q, Wu Y, et al. Cumulative triglyceride-glucose index is a risk for CVD: a prospective cohort study. Cardiovasc Diabetol. 2022;21(1):22","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10745_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s13098-024-01433-6","volume":"16","author":"H Cui","year":"2024","unstructured":"Cui H, Liu Q, Zhao Z, et al. Interacting and joint effects of triglyceride-glucose index and blood pressure on cardiovascular diseases risk: a prospective cohort study. Diabetol Metab Syndr. 2024;16(1):188","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"10745_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u2013612","journal-title":"Ann Intern Med"},{"issue":"4","key":"10745_CR21","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/j.ajkd.2023.08.016","volume":"83","author":"Y Li","year":"2024","unstructured":"Li Y, Wu S, Gao J, et al. Association of stroke with metabolic dysfunction-associated fatty liver disease with and without CKD. Am J Kidney Dis. 2024;83(4):477\u2013488","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"10745_CR22","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1136\/heartjnl-2019-315299","volume":"105","author":"M Woodward","year":"2019","unstructured":"Woodward M. Rationale and tutorial for analysing and reporting sex differences in cardiovascular associations. Heart. 2019;105(22):1701\u20131708","journal-title":"Heart"},{"issue":"10355","key":"10745_CR23","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S0140-6736(22)01441-6","volume":"400","author":"M Walli-Attaei","year":"2022","unstructured":"Walli-Attaei M, Rosengren A, Rangarajan S, et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet. 2022;400(10355):811\u2013821","journal-title":"Lancet"},{"key":"10745_CR24","doi-asserted-by":"publisher","first-page":"154779","DOI":"10.1016\/j.metabol.2021.154779","volume":"120","author":"S Liu","year":"2021","unstructured":"Liu S, Wang J, Wu S, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis. Metabolism. 2021;120:154779","journal-title":"Metabolism"},{"issue":"2","key":"10745_CR25","doi-asserted-by":"publisher","first-page":"100064","DOI":"10.59717\/j.xinn-med.2024.100064","volume":"2","author":"M Zheng","year":"2024","unstructured":"Zheng M, Wang X, Yin Y, et al. New-onset age of metabolic-associated fatty liver disease and incident cardiovascular diseases: findings from prospective cohort. The Innov Med. 2024;2(2):100064","journal-title":"The Innov Med"},{"issue":"15","key":"10745_CR26","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.3748\/wjg.v26.i15.1792","volume":"26","author":"J Zeng","year":"2020","unstructured":"Zeng J, Yang RX, Sun C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020;26(15):1792\u20131804","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10745_CR27","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/ajg.2016.318","volume":"112","author":"A Feldman","year":"2017","unstructured":"Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, et al. Clinical and metabolic characterization of lean caucasian subjects with non-alcoholic fatty liver. Am J Gastroenterol. 2017;112(1):102\u2013110","journal-title":"Am J Gastroenterol"},{"key":"10745_CR28","doi-asserted-by":"publisher","first-page":"154112","DOI":"10.1016\/j.prp.2022.154112","volume":"238","author":"A Rastogi","year":"2022","unstructured":"Rastogi A, Rath I, Varadarajan A, Ramakrishna G, Bihari C, Maiwall R. Non-alcoholic fatty liver disease (NAFLD) in lean individuals - Single centre large cohort clinicopathologic and immunophenotypic study. Pathol Res Pract. 2022;238:154112","journal-title":"Pathol Res Pract"},{"key":"10745_CR29","doi-asserted-by":"crossref","unstructured":"Souza M, Diaz I, Al-Sharif L. Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals. Hepatol Int. 2024 Aug 8.","DOI":"10.1007\/s12072-024-10716-z"},{"issue":"1","key":"10745_CR30","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/HEP.0000000000000329","volume":"78","author":"O Nabi","year":"2023","unstructured":"Nabi O, Lapidus N, Boursier J, de Ledinghen V, Petit JM, Kab S, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study). Hepatology. 2023;78(1):272\u2013283","journal-title":"Hepatology"},{"issue":"10","key":"10745_CR31","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.cgh.2022.11.019","volume":"21","author":"J Ha","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023;21(10):2496-2507.e5","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10745_CR32","doi-asserted-by":"crossref","unstructured":"Alarabi M, Pan Z, Romero-G\u00f3mez M, George J, Eslam M. Telomere length and mortality in lean MAFLD: the other face of metabolic adaptation. Hepatol Int. 2024 Jun 20.","DOI":"10.1007\/s12072-024-10701-6"},{"key":"10745_CR33","doi-asserted-by":"publisher","first-page":"104617","DOI":"10.1016\/j.phrs.2019.104617","volume":"152","author":"D Raj","year":"2020","unstructured":"Raj D, Tomar B, Lahiri A, et al. The gut-liver-kidney axis: novel regulator of fatty liver associated chronic kidney disease. Pharmacol Res. 2020;152:104617","journal-title":"Pharmacol Res"},{"issue":"1","key":"10745_CR34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18(1):55\u201366","journal-title":"Nat Rev Endocrinol"},{"issue":"11","key":"10745_CR35","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/s41575-023-00800-4","volume":"20","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Zelber-Sagi S, Henry L, et al. Lifestyle interventions in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2023;20(11):708\u2013722","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10745_CR36","doi-asserted-by":"publisher","first-page":"290","DOI":"10.5009\/gnl210084","volume":"16","author":"Y Kim","year":"2022","unstructured":"Kim Y, Han E, Lee JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022;16(2):290\u2013299","journal-title":"Gut Liver"},{"key":"10745_CR37","doi-asserted-by":"crossref","unstructured":"Feng B, Li F, Lan Y, et al. Statin use and development and progression of non-alcohol fatty liver disease based on ultrasonography: a cohort study. J Clin Endocrinol Metab. 2024 Aug 16:dgae546.","DOI":"10.1210\/clinem\/dgae546"},{"issue":"1","key":"10745_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41387-024-00294-2","volume":"14","author":"M Dallio","year":"2024","unstructured":"Dallio M, Sangineto M, Romeo M, et al. The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition. Nutr Diabetes. 2024;14(1):33","journal-title":"Nutr Diabetes"},{"issue":"1","key":"10745_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.hbpd.2023.10.003","volume":"23","author":"HK Huang","year":"2024","unstructured":"Huang HK, Li YM, Xu CF. Pre-MASLD: should it be defined separately? Hepatobiliary Pancreat Dis Int. 2024;23(1):1\u20133","journal-title":"Hepatobiliary Pancreat Dis Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10745-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10745-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T12:45:08Z","timestamp":1740228308000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10745-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10745"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10745-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"type":"print","value":"1936-0533"},{"type":"electronic","value":"1936-0541"}],"subject":[],"published":{"date-parts":[[2024,11,23]]},"assertion":[{"value":"7 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"The study was performed according to the guidelines of the Helsinki Declaration and was approved by the Ethics Committee of Kailuan General Hospital (approval number: 2006\u201305). All participants were agreed to take part in the study and provided informed written consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}